\$25 billion (1% of the world's annual energy budget) should be spent on research and development to remove any lingering doubts.

This may seem an expensive insurance premium, but no price can realistically be set on the importance of confronting what is likely to be the major challenge of the 21st century. The recent experience of California suggests what consequence to an energy-dependent world could result from our collective failure to meet this challenge.

SIR IAN LLOYD*

Bakers House, Priors Dean, Petersfield, Hants, UK. E-mail: ian@sirianlloyd, freeserve.co.uk *Past president, U. K. Parliamentary and Scientific Committee, and chairman, Select Committee on Energy, 1980–90

- References and Notes
- U.K. House of Commons Energy Committee, 6th Report: Energy Policy Implications of the Greenhouse Effect, HMSO 192, vols. 1 to 111, 4.7.1989.
- Royal Society and Royal Academy of Engineering, *Nuclear Energy—The Future Climate*, June 1999 (www.royalsoc.ac.uk/policy/index.html); *The Role of the Renewables Directive in Meeting Kyoto Targets*, October 2000 (www.raeng.org.uk/Statements/State-ments.htm).

Health Impacts of Climate Change

ON 3 APRIL, THE NATIONAL ACADEMY OF Sciences (NAS) released a report on the potential impacts of climate change on infectious diseases entitled "Under the Weather: Climate, Ecosystems, and Infectious Disease" (1). News articles on the report implied that the study findings contradict or at least are much less alarming than those recently reported from the Intergovernmental Panel on Climate Change (IPCC) (2) (released 18 March). This general conclusion is inappropriate, for a number of reasons.

First, the two studies had a different purpose. The NAS study is foremost an assessment of the capability of predictive models and early warning systems to forecast infectious diseases. The main purpose of the IPCC study was to review the peer-reviewed and published literature on the entire range of

Letters to the Editor

Letters (~300 words) discuss material published in *Science* in the previous 6 months or issues of general interest. They can be submitted by e-mail (science_letters@aaas.org), the Web (www.letter2science.org), or regular mail (1200 New York Ave., NW, Washington, DC 20005, USA). Letters are not acknowledged upon receipt, nor are authors generally consulted before publication. Whether published in full or in part, letters are subject to editing for clarity and space. potential health impacts of global warming and to assess both the severity of that threat and the state of the science about human health impacts from climate change.


Second, the scope of the two reports is significantly different. The NAS study centers on infectious diseases only. IPCC experts, on the other hand, reviewed studies that examined the actual (that is, historically observed) and potential impacts of climate variability and change on many aspects of human health, including heat stress, air pollution, health threats from storms and floods, and infectious diseases.

Third, the IPCC emphasis on vulnerability and adaptation is stronger than that in the NAS report. Both the IPCC and the NAS reports, however, go beyond a mere discussion of the direct links among climate, the environment, and health. Each report places potential health impacts into the broader context of societal capacity to cope with health challenges of any source.

Having clarified the differences between the two reports, it is instructive to compare the key findings of both, revealing significant congruence. The health experts writing the NAS and IPCC reports agree that a changing climate affects the spread of infectious diseases and that the geographic range of infectious diseases such as malaria and dengue fever might expand. Both reports note that vulnerability and the ability to cope with the threat from infectious diseases ultimately determine the severity of the impact on human populations. They also acknowledge that, although we know that climate change affects the spread of infectious diseases, the world health community cannot vet predict when or where exactly this will happen or how large the threat of these diseases will be to particular populations.

However, there is a strong sense in both reports that the uncertainties related to the health impacts of climate change warn us that we should take the issue seriously. Neither suggests that the inability to predict exactly when and how infectious diseases will spread should be used as an excuse for inaction on human health or climate change. Mitigating climate change through emission reductions will reduce a significant source of health stressors, while limiting the extent to which disease vectors and agents are forced into unknown territory. Likewise, common sense preventive actions such as better sanitation, access to health care, and new vaccines and drugs will strengthen the capacity of populations to contain the spread of infectious diseases or to treat them more effectively when they occur.

PIM MARTENS,¹ SUSANNE C. MOSER² ¹International Centre for Integrative Studies, Maastricht University, P.O. Box 616 6200 MD Maastricht, the Netherlands. E-mail: p.martens@



Custom

Shotgun Libraries

- Ready in 1-2
 Weeks
 Clones Shipped
- in 96 or 384-Well Plates

Custom Gridding & Arraying

- Arraying of Libraries to Nylon Filters
- Up to 29,000

Double Spotted Clones/Filter

Shotgun Sequencing

- Clones Picked
 & Prepped
- High Throughput Sequencing & Assembly
 Full-Length Sequencing





THE FASTEST SERVICE IN THE INDUSTRY, WITH GUARANTEED RESULTS.

Tel:1-800-720-4363 Web: www.seqwright.com

SCIENCE'S COMPASS

icis.unimaas.nl; ²Global Environment Program, Union of Concerned Scientists, Cambridge, MA 02238, USA. E-mail: smoser@ucsusa.org

References

- National Research Council, Under the weather: Climate, Ecosystems, and Infectious Disease (National Academy Press, Washington, DC, 2001).
- A. J. McMichael, A. Githeko, in *Climate Change 2001:* Impacts, Adaptation, and Vulnerability, IPCC, in press.

Describing the Release of Sequence Data

RICHARD W. HYMAN'S LETTER ENTITLED "Sequence data: posted vs. published" (2 Feb., p. 827) is not in accord with the data release policies adopted by the National Institutes of Health and the U.S. Department of Energy. That policy statement begins, "[The National Human Genome Research Institute's] policy for release and deposition of DNA sequence data was devised to make sequence data available to the research community as soon as possible for free, unfettered use" (1).

Nowhere in that document is there any implication that sequencing centers would retain veto power over the use of prepublication data in academic publications. Just the opposite. The purpose of prepublication release is to allow the academic community to make full use of genome sequence data in all aspects of research as soon as possible. That such work should result in academic publication is the goal of the data release policy. Sequencing centers uncomfortable with this data release policy were certainly free to seek

funding through other sources, and at least one center did just that, with great success.

I disagree with Hyman's statement that it is easy to recognize prepublication data in GenBank. GenBank policy dictates that only the depositing authors can modify a sequence entry, and many authors fail to update entries to reflect progress in the peer review process. It is difficult for database

providers to make these updates because the title, authors, and journal may change in the course of manuscript review and resubmission. Many entries in GenBank are annotated as "unpublished submission," when in fact papers describing the data by the authors who deposited the sequence have appeared in the peer-reviewed literature.

Sequence finishing is an ongoing process, and we will undoubtedly be publishing revisions and additional annotations on the human genome for many years. To delay publication of derivative work until a center signs

"[P]republication

release...allow[s] the

academic community

to make full use of

genome sequence

data...as soon

as possible."

off on a final version is not feasible, because there will not be a fully finished human genome sequence for many years to come, if ever. Particularly for sequence in the draft phase, the data are a moving target. It is therefore important that publications based on draft sequence cite the source and date of the entry.

Finally, submission of data to GenBank is a

form of electronic publication (2). Data appear in GenBank only with the consent of a submitting author or through journal scanning. GenBank entries establish publication date for patent purposes, and GenBank accession numbers are routinely used as a mecha-

Announcing WOMEN'S INTERNATIONAL SCIENCE COLLABORATION (WISC) PROGRAM 2001–2002 AAAS PROGRAM ON EUROPE AND CENTRAL ASIA

OVERVIEW

The Women's International Science Collaboration (WISC) Program is funded by the National Science Foundation (NSF) and administered by the Program on Europe and Central Asia of the American Association for the Advancement of Science (AAAS). Because the application rate of women scientists and engineers to the Central and Eastern Europe Program of the Division of International Programs has been disproportionately low, the goal of this Program is to increase the participation of women as PIs and co-PIs in international research projects. This program provides grants to individual US scientists who plan to establish new research partnerships with their colleagues in Central/Eastern Europe (CEE) and the Newly Independent States of the former Soviet Union (NIS). The grant, up to \$4,000, will provide travel and living support for the US woman scientist and when appropriate, an additional grant of \$4,000 to her American male or female co-PI. Each scientist will be responsible for arranging accommodations. The grant does not cover salary or institutional expenses (e.g. overhead). US scientists can spend up to four weeks in the partner country to develop a research program

and design. The grantee's home institution will be responsible for overseeing the grantee's adherence to NSF and federal guidelines regarding administration of the grant.

ELIGIBILITY

Men and women scientists who have their Ph.D.s or equivalent research experience are eligible to apply. Applications from male co-PIs must be accompanied by an application from a female co-PI as part of a US research team. They must be US citizens or permanent residents of the US. Male and female graduate students (Ph.D. candidates) are also eligible to apply, if they will be conducting research in an established Ph.D. program in the US and will be traveling with their Ph.D. advisor and will serve as co-PI on future proposals. Government employees can only apply if they also are affiliated with another institution eligible to receive NSF grants (e. g. an adjunct professorship at a university).

DEADLINES


March 15, 2001 (notification by May 1) July 15, 2001 (notification by October 15) January 15, 2002 (notification by April 15)

INFORMATION



For questions, please contact Karen Grill at e-mail: kgrill@aaas For complete details of the WISC program and for forms, please review our website at: http://www.aaas.org/international/eca/wisc shtml





1066